Application of Botulinum Toxin in Pain Management

Sim, Woo Seog

doi:10.3344/kjp.2011.24.1.1

Cited by 56 publications

(49 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As explained above, the findings of this study are consistent with the analgesic effects of Botulinum Toxin type A [22][23][24][25][26][27] , reinforcing the fact that it can be used for purposes other than spasticity, [28][29][30][31][32][33] or migraine 23 as they are the indications authorized by the FDA in Colombia at present 5 .…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

Effectiveness of botulinum toxin type A for pain control in children with spastic cerebral palsy

Palacios

Valencia

2018

Rev Col Med Fis Reh

View full text Add to dashboard Cite

RESUMENSe realizó un estudio analítico longitudinal prospectivo de antes y después de 12 pacientes pediátricos entre los 2 y los 18 años con parálisis cerebral espástica con limitación para la comunicación, valorándose la presencia de dolor mediante el uso de la escala FLACC; los participantes tenían indicación de aplicación de toxina botulínica tipo A para el control de espasticidad. Posterior a esto se realizó nuevamente la evaluación de la presencia de dolor a la semana y al mes, esto con el objetivo de determinar si hay cambios objetivos en los pacientes que puedan favorecer una mejor calidad de vida. Materiales y métodos: Estudio analítico no experimental longitudinal prospectivo de antes y después para muestras relacionadas de una cohorte de niños entre 0 y 18 años con diagnóstico de parálisis cerebral espástica y presencia de dolor reportado por los padres. Se realizó el test estadístico T-student para muestras relacionadas (emparejadas o apareadas) analizando los resultados de la escala FLACC del dolor. Resultados: Se reunieron 15 pacientes de los cuales por falta en los controles y falta de datos proporcionados por los padres se perdieron 3 casos obteniéndose un total de 12 pacientes incluidos en el estudio, en el cual se encontraron, mediante el uso de la escala FLACC en la primera valoración (FLACC1) siete pacientes (58,3%) con dolor moderado, cuatro (33,3%) con dolor severo y uno (8,3%) con dolor leve; en la segunda valoración, una semana después de la aplicación de material miorelajante (FLACC2) los resultados evidenciaron que cuatro (33.3%) presentaban dolor moderado y ocho (66,7%) dolor leve. Posteriormente, en la tercera valoración al mes del procedimiento (FLACC3) tres (25%) de los pacientes presentaban dolor moderado, ocho (66,7%) dolor leve y uno (8,3%) de ellos ya no presentaba manifestaciones de dolor. Esto demostró que existen diferencias significativas entre los valores de dolor antes y después de la aplicación del material miorelajante, sugiriendo la efectividad del control del dolor con la aplicación de toxina botulínica tipo A. Conclusiones: La aplicación de la escala FLACC a pacientes con parálisis cerebral espástica permite una valoración objetiva del nivel de dolor en los pacientes con limitación para la comunicación y la aplicación de toxina botulínica como material miorelajante tiene un efecto benéfico significativo en la disminución del dolor en este grupo poblacional. Palabras clave: Toxina botulínica tipo A, escala FLACC, dolor en niños, espasticidad, lesión cerebral. indication for the administration of Botulinum Toxin type A for the control of spasticity. After this, the evaluation of the presence of pain was performed a week and a month after de administration of the myorelaxant material, in order to determine if there were any objective changes that may favor a better quality of life. Materials and methods: A Prospective longitudinal non-experimental analytical before and after for related samples study was performed in children between 0 and 18 years of age with a diagnosis...

show abstract

Section: Discussionsupporting

confidence: 75%

“…In 2011, The Korean Journal of Pain published an article that analyzed the mechanism of action of botulinum toxin and mentioned how it could be used for myofascial pain syndrome, chronic low back pain, headache, arthralgia, chronic pelvic pain, and neuropathic pain 22 .…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of botulinum toxin type A for pain control in children with spastic cerebral palsy

Palacios

Valencia

2018

Rev Col Med Fis Reh

View full text Add to dashboard Cite

show abstract

“…A variety of studies evaluated the impact of BoTA on temporary muscular paralysis and relief of the tension on the sites of wound, which may aid to prevent the hypertrophy and hyperpigmentation of wound sites [49,50]. BoTA is also widely investigated and applied in pain management of myofascial syndrome, headaches, arthritis, and neuropathic pain by induction of muscle chemodenervation via preventing the release of neurotransmitters such as acetylcholine and noradrenaline [51,52]. A broad range of all these BoTA utilization may a rm its safety in human body, which has been addressed in previous studies by demonstrating the remarkably effective and safe results of BoTA treatment for the facial aesthetic purposes, which obtained from 1474 subjects [53], and quantitatively safe and tolerable pro les of BoTA utilization from the meta-analysis involving 2309 subjects [54].…”

Section: Discussionmentioning

confidence: 99%

Non-invasive intra-uterine administration of Botulinum Toxin A enhances endometrial angiogenesis and improves the rates of embryo implantation

Koo¹,

Yoon

Hong³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Endometrial angiogenesis plays crucial roles in determining the endometrial receptivity. Defects in endometrial receptivity often cause repeated implantation failure, which is one of the major unmet needs for infertility and contributes a major barrier to the assisted reproductive technology. Despite the numerous extensive research work, there are currently no effective evidence-based treatments to prevent or cure this condition.Method. As a non-invasive treatment strategy, Botulinum toxin A (BoTA) was administered into one side of mouse uterine horns and saline was infused into the other side of horns for the control. Impact of BoTA was assessed in the endometrium at 3 or 8 days after infusion.Results. We demonstrated that BoTA administration enhances the capacity of endothelial cell tube formation and sprouting. The intrauterine BoTA administration significantly induced endometrial angiogenesis displaying increased numbers of vessel formation and expression levels of related-marker genes. Moreover, BoTA intrauterine application promoted the endometrial receptivity and the rates of embryo implantation were improved with BoTA treatment with no morphologically retarded embryos. Conclusion. Intrauterine BoTA treatment has a beneficial effect on vascular reconstruction of functional endometrium prior to embryo implantation by increasing endometrial blood flow near the uterine cavity suggesting BoTA treatment as a potential therapeutic strategy for patients who are suffering from repeated implantation failure with the problems with endometrial receptivity.

show abstract

“…Allodynia or descriptors such as a burning pain or electric shock sensation can aid the diagnosis. Proposed mechanisms to the development of CPSP include an increase in neuronal hyperexcitability, alterations in spinothalamic tract function or loss of normal inhibition of pain [4].…”

Section: Discussionmentioning

confidence: 99%

The Benefit of Botulinum Toxin A in the Management of Central Post Stroke Pain: A Case Report

Shippen¹

2017

JNSK

View full text Add to dashboard Cite

Purpose: Spasticity and pain are common complications of stroke. Pain following stroke is multi factorial and can be due to musculoskeletal problems, painful spasticity or central post stroke pain. Botulinum Toxin A is the first line pharmacotherapy in spasticity management and increasing evidence has shown benefits in neuropathic pain.Results: This case report demonstrates the benefit of Botulinum Toxin A in the management of central post-stroke pain with elbow flexor spasticity. The clinical characteristics of the pain were neuropathic and the severity was greater than expected given the degree of spasticity. The pain responded to Botulinum Toxin treatment within a few days, independently of the improvement in spasticity and the effect was continued over six cycles of treatment. Conclusion:Management of central post stroke pain is challenging due systemic side effects of oral medications. Botulinum Toxin A has increasingly being shown to benefits in neuropathic pain either through blockade of nociceptive substances or acting on central transmission of pain. Although the treatment in our case was given for spasticity management, the patient had unexpected and significant improvement in pain prior to improvement in range of movement. Given the increasing evidence in use of Botulinum Toxin A in neuropathic pain, we feel this may be a possible future treatment option for central post-stroke pain

show abstract

Application of Botulinum Toxin in Pain Management

Cited by 56 publications

References 26 publications

Effectiveness of botulinum toxin type A for pain control in children with spastic cerebral palsy

Effectiveness of botulinum toxin type A for pain control in children with spastic cerebral palsy

Non-invasive intra-uterine administration of Botulinum Toxin A enhances endometrial angiogenesis and improves the rates of embryo implantation

The Benefit of Botulinum Toxin A in the Management of Central Post Stroke Pain: A Case Report

Contact Info

Product

Resources

About